Literature DB >> 2869106

Characterization of opioid receptor subtypes in solution.

C D Demoliou-Mason, E A Barnard.   

Abstract

Stable opioid receptor binding activity that retains distinct subtype specificities (mu, delta, and kappa) has been obtained in high yields in digitonin extracts of rat brain membranes that had been preincubated with Mg2+ prior to solubilization. The dependence on Mg2+ ions for receptor activity is also expressed in the soluble state, where the presence of Mg2+ leads to high-affinity and high-capacity opioid peptide binding to the delta, mu, and kappa sites (the latter subtype measured by the binding of [3H]dynorphin1-8). Binding of opiate alkaloids to soluble receptor sites is less dependent on Mg2+ than is opioid peptide binding. Soluble opioid binding activity shows the same sensitivity to Na+ ions and guanine nucleotides as the membrane-bound receptor. The ligand-receptor interactions give evidence of strong positive cooperativity, which is interpreted in terms of association-dissociation of receptor subunits on ligand binding in solution. Binding of enkephalin peptides is associated with the large macromolecules present (apparent Stokes radii greater than 60 A), whereas both those and several small species present (less than 60 A) bind opiate alkaloids and dynorphin1-8.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869106     DOI: 10.1111/j.1471-4159.1986.tb00627.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  2 in total

1.  Correlation of apparent affinity values from H3-receptor binding assays with apparent affinity (pKapp) and intrinsic activity (alpha) from functional bioassays.

Authors:  E A Harper; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

2.  Single potassium channels opened by opioids in rat locus ceruleus neurons.

Authors:  M Miyake; M J Christie; R A North
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.